Clinical-stage biotech Windward Bio successfully listed on the Nasdaq on November 13, 2026, pricing its IPO at $17.00 per share. The stock closed its first trading day at $28.50, representing a 68% gain and valuing the company at approximately $1.69 billion. The firm is currently advancing a pipeline of ultra-long-acting antibody medicines, including lead program WIN378, which is in Phase 2/3 trials for severe uncontrolled asthma.
Bullish
🤖 55%
Windward Bio completed its Nasdaq IPO on November 13, 2026 at $17.00 per share and closed its first trading day at $28.50, up 68%, with a market capitalization of about $1.69 billion. A debut this strong signals robust investor demand, which can support the price in the following sessions. However, the pop already occurred, and the company remains clinical-stage with no approved products, so much of the positive news is already in the price.
Catalysts
- ▲ Nasdaq IPO completed November 13, 2026 at $17.00 per share
- ▲ First-day close at $28.50, up 68% from IPO price, market cap around $1.69 billion
Risk Factors
- ▼ The 68% first-day gain already happened, so late buyers enter at a much higher valuation
- ▼ Clinical-stage pipeline with no marketed products; WIN378 and WIN027 are still in trials